Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
At a glance
- Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary)
- Indications Pelvic inflammatory disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 29 Jan 2018 Planned End Date changed from 26 Feb 2018 to 1 Mar 2018.
- 20 Dec 2017 Planned End Date changed from 28 Mar 2018 to 26 Feb 2018.
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.